

Clovis Oncology, Inc.  
Form 8-K  
September 04, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): September 3, 2014**

**Clovis Oncology, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**  
**2525 28<sup>th</sup> Street, Suite 100**

**001-35347**  
**(Commission**  
  
**File Number)**

**90-0475355**  
**(I.R.S. Employer**  
  
**Identification No.)**  
**80301**

**Boulder, Colorado**  
**(Address of principal executive**  
**offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (303) 625-5000**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On September 3, 2014, Clovis Oncology, Inc. (the Company ) issued a press release announcing the pricing of \$250 million aggregate principal amount of its 2.50% convertible senior notes due 2021 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Company also granted the initial purchasers of the notes a 30-day option to purchase up to an additional \$37.5 million aggregate principal amount of such notes on the same terms and conditions. A copy of the Company s press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. This current report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy the notes.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits:

99.1 Press Release, dated September 3, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 3, 2014

**CLOVIS ONCOLOGY, INC.**

By: /s/ Erle T. Mast

Name: Erle T. Mast

Title: Executive Vice President and Chief Financial Officer

- 3 -

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release, dated September 3, 2014